JP2005529947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529947A5 JP2005529947A5 JP2004512782A JP2004512782A JP2005529947A5 JP 2005529947 A5 JP2005529947 A5 JP 2005529947A5 JP 2004512782 A JP2004512782 A JP 2004512782A JP 2004512782 A JP2004512782 A JP 2004512782A JP 2005529947 A5 JP2005529947 A5 JP 2005529947A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- medicament
- pharmaceutically acceptable
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010000496 acne Diseases 0.000 claims description 17
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 8
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims description 8
- 239000004098 Tetracycline Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 229960002227 clindamycin Drugs 0.000 claims description 7
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 7
- 210000002374 sebum Anatomy 0.000 claims description 7
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims description 7
- 229960002180 tetracycline Drugs 0.000 claims description 7
- 229930101283 tetracycline Natural products 0.000 claims description 7
- 235000019364 tetracycline Nutrition 0.000 claims description 7
- 150000003522 tetracyclines Chemical class 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 4
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- PDSNLYSELAIEBU-UHFFFAOYSA-N Longifolene Chemical compound C1CCC(C)(C)C2C3CCC2C1(C)C3=C PDSNLYSELAIEBU-UHFFFAOYSA-N 0.000 claims description 4
- ZPUKHRHPJKNORC-UHFFFAOYSA-N Longifolene Natural products CC1(C)CCCC2(C)C3CCC1(C3)C2=C ZPUKHRHPJKNORC-UHFFFAOYSA-N 0.000 claims description 4
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002916 adapalene Drugs 0.000 claims description 4
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 4
- 229960002255 azelaic acid Drugs 0.000 claims description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 4
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims description 4
- 229940117948 caryophyllene Drugs 0.000 claims description 4
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims description 4
- IRAQOCYXUMOFCW-CXTNEJHOSA-N cedrene Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@H]1C(C)=CC2 IRAQOCYXUMOFCW-CXTNEJHOSA-N 0.000 claims description 4
- 239000004927 clay Substances 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- IRAQOCYXUMOFCW-UHFFFAOYSA-N di-epi-alpha-cedrene Natural products C1C23C(C)CCC3C(C)(C)C1C(C)=CC2 IRAQOCYXUMOFCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000013003 healing agent Substances 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 235000011929 mousse Nutrition 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229940055019 propionibacterium acne Drugs 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229960000565 tazarotene Drugs 0.000 claims description 4
- 241000186427 Cutibacterium acnes Species 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 210000003491 skin Anatomy 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 12
- 241000192125 Firmicutes Species 0.000 claims 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000003921 oil Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- QPVSSARHYZXAPM-UHFFFAOYSA-N 2-amino-2-oxoethanesulfonic acid Chemical compound NC(=O)CS(O)(=O)=O QPVSSARHYZXAPM-UHFFFAOYSA-N 0.000 claims 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 3
- 241000191940 Staphylococcus Species 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims 3
- 125000000017 cortisol group Chemical group 0.000 claims 3
- 210000002615 epidermis Anatomy 0.000 claims 3
- 229960000890 hydrocortisone Drugs 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 3
- 229960002009 naproxen Drugs 0.000 claims 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims 3
- 238000011200 topical administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- -1 Hidoroko Le Chizon) Substances 0.000 description 1
- 101000655610 Planobispora rosea Thiocillin GE2270 Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000002995 comedolytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02013268 | 2002-06-17 | ||
| EP02013268.4 | 2002-06-17 | ||
| PCT/EP2003/005989 WO2003105881A1 (en) | 2002-06-17 | 2003-06-06 | Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529947A JP2005529947A (ja) | 2005-10-06 |
| JP2005529947A5 true JP2005529947A5 (enExample) | 2006-10-19 |
| JP4723857B2 JP4723857B2 (ja) | 2011-07-13 |
Family
ID=29724391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004512782A Expired - Fee Related JP4723857B2 (ja) | 2002-06-17 | 2003-06-06 | アクネの治療のためのｇｅ２２７０因子ａ３のアミド誘導体の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7655676B2 (enExample) |
| EP (1) | EP1553967B1 (enExample) |
| JP (1) | JP4723857B2 (enExample) |
| KR (1) | KR20050026401A (enExample) |
| AR (1) | AR039682A1 (enExample) |
| AT (1) | ATE509633T1 (enExample) |
| AU (1) | AU2003242647B2 (enExample) |
| BR (1) | BR0305070A (enExample) |
| CA (1) | CA2489705C (enExample) |
| CY (1) | CY1111734T1 (enExample) |
| DK (1) | DK1553967T3 (enExample) |
| ES (1) | ES2364269T3 (enExample) |
| NO (1) | NO333162B1 (enExample) |
| PT (1) | PT1553967E (enExample) |
| SI (1) | SI1553967T1 (enExample) |
| TW (1) | TWI329650B (enExample) |
| WO (1) | WO2003105881A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR060977A1 (es) * | 2006-05-31 | 2008-07-23 | Novartis Ag | Aminotiazoles y sus usos |
| EA200900816A1 (ru) | 2006-12-20 | 2009-12-30 | Новартис Аг | Антибактериальные соединения и способы их получения |
| CA2688621A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Macrocycles and their uses |
| NZ585788A (en) | 2007-12-12 | 2011-07-29 | Novartis Ag | Aminothiazoles and their uses |
| PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
| FR3004939B1 (fr) * | 2013-04-26 | 2015-05-22 | Oreal | Huile essentielle de satureja montana a forte teneur en geraniol, et utilisation pour traiter les peaux grasses et/ou les defauts esthetiques associes |
| DE102013215828A1 (de) * | 2013-08-09 | 2015-02-12 | Beiersdorf Ag | Gelförmiges Sonnenschutzmittel mit Fettalkoholen |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988009788A1 (en) * | 1987-06-12 | 1988-12-15 | Molecular Design International, Inc. | Topical prodrugs for treatment of acne and skin diseases |
| LU86865A1 (fr) * | 1987-05-06 | 1989-01-19 | Oreal | Nouveaux retinoates d'ammonium quaternaires,leur utilisation en cosmetique et en dermopharmacie |
| ES2066914T3 (es) | 1989-07-04 | 1995-03-16 | Lepetit Spa | Factores a1, a2, a3 y h del antibiotico ge 2270. |
| JP2693859B2 (ja) | 1990-09-28 | 1997-12-24 | 高砂香料工業株式会社 | 尋常性▲ざ▼瘡用皮膚外用剤 |
| IL100572A (en) | 1991-01-03 | 1997-01-10 | Lepetit Spa | Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them |
| JP2907640B2 (ja) | 1992-06-29 | 1999-06-21 | 高砂香料工業株式会社 | 尋常性ざ瘡用皮膚外用剤 |
| JP2937667B2 (ja) | 1992-11-19 | 1999-08-23 | 高砂香料工業株式会社 | 尋常性ざ瘡用皮膚外用剤 |
| ES2115424T3 (es) | 1995-02-07 | 1998-06-16 | Biosearch Italia Spa | Derivados prolin-amidicos basicos de los antibioticos ge 2270 y similares a ge 2270. |
| DE69718442T2 (de) | 1996-02-14 | 2003-04-30 | Biosearch Italia S.P.A., Gerenzano | Derivate des antibiotisch wirkenden faktors ge2270 |
| AUPN892496A0 (en) * | 1996-03-25 | 1996-04-18 | Technical Consultancy Services Pty Limited | Acne treatment |
| US6009225A (en) * | 1998-05-26 | 1999-12-28 | Ray; Craig D. | Fiber optic drop splice closure and related methods |
-
2003
- 2003-06-06 KR KR1020047020329A patent/KR20050026401A/ko not_active Ceased
- 2003-06-06 ES ES03759919T patent/ES2364269T3/es not_active Expired - Lifetime
- 2003-06-06 JP JP2004512782A patent/JP4723857B2/ja not_active Expired - Fee Related
- 2003-06-06 AT AT03759919T patent/ATE509633T1/de active
- 2003-06-06 US US10/518,802 patent/US7655676B2/en active Active
- 2003-06-06 BR BR0305070-0A patent/BR0305070A/pt not_active Application Discontinuation
- 2003-06-06 SI SI200332001T patent/SI1553967T1/sl unknown
- 2003-06-06 AU AU2003242647A patent/AU2003242647B2/en not_active Ceased
- 2003-06-06 WO PCT/EP2003/005989 patent/WO2003105881A1/en not_active Ceased
- 2003-06-06 PT PT03759919T patent/PT1553967E/pt unknown
- 2003-06-06 DK DK03759919.8T patent/DK1553967T3/da active
- 2003-06-06 CA CA2489705A patent/CA2489705C/en not_active Expired - Fee Related
- 2003-06-06 EP EP03759919A patent/EP1553967B1/en not_active Expired - Lifetime
- 2003-06-12 TW TW092115959A patent/TWI329650B/zh not_active IP Right Cessation
- 2003-06-17 AR ARP030102134A patent/AR039682A1/es not_active Application Discontinuation
-
2004
- 2004-02-16 NO NO20040662A patent/NO333162B1/no not_active IP Right Cessation
-
2011
- 2011-08-04 CY CY20111100749T patent/CY1111734T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6589086B2 (ja) | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 | |
| US9107844B2 (en) | Topical skin treating compositions | |
| JP2009500336A (ja) | 局所用皮膚治療組成物 | |
| EA008813B1 (ru) | Фармацевтические и/или косметические системы дозирования для местного применения | |
| US20040167223A1 (en) | Topical antibacterial formulations | |
| JPH10509437A (ja) | 防臭、抗菌及び保存剤組成物並びにそれらを使用する方法 | |
| US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
| JP2014501776A (ja) | 座瘡の治療のためのメラトニン及び殺菌剤又は抗菌剤 | |
| JP2018507219A (ja) | 局所製剤 | |
| JP2011528377A (ja) | 座瘡治療のための方法及び物質 | |
| JP2011093835A (ja) | 皮膚外用剤 | |
| WO2014042604A1 (en) | Clindamycin phosphate, salicylic acid and tea tree oil combinations | |
| US20250170085A1 (en) | Topical formulation to decrease skin inflammation or redness | |
| JP2000095683A (ja) | 皮膚外用剤 | |
| JP4723857B2 (ja) | アクネの治療のためのｇｅ２２７０因子ａ３のアミド誘導体の使用 | |
| JP2009167139A (ja) | 外用組成物 | |
| WO2014076092A1 (en) | A proton pump inhibitor for use in a method of treating dermatological diseases in canine | |
| US20230099068A1 (en) | Topical antimicrobial formulations | |
| JP2006282650A (ja) | 皮膚化粧料 | |
| Krowchuk | Topical therapies for acne | |
| JP2017114769A (ja) | ニキビ治療用外用医薬組成物 |